The drug was developed to block nerve growth factor, a protein associated with pain. Johnson & Johnson’s fulranumab was not the only product to be placed on clinical hold due to a possible link to a bone disorder that would require a total joint replacement. Regeneron Pharmaceuticals has also had its pain drug for osteoarthritis put on hold.
Read the news report about the FDA’s hold on Johnson & Johnson’s fulranumab.
Read other coverage about the FDA:
– New Test Measuring DNA Methylation Levels Could Help Detect CRC
– Pharmaceutical Companies Submit Pain Management Drug to FDA
– FDA Accepts Drug Application for Postsurgical Pain Management
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
